A Phase 1 Open-Label, Dose Escalation Study to Determine the Optimal Dose, Safety, and Activity of AAV2hAQP1 in Subjects With Radiation-Induced Parotid Gland Hypofunction and Xerostomia

NCT ID: NCT04043104

Last Updated: 2023-04-24

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 24 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2019-06-30
• Study Completion Date: 2023-03-28

Brief Summary

Open-label, non-randomized, dose escalation trial of AAV2hAQP1 administered via Stensen's duct to a single or both parotid glands in subjects with radiation-induced xerostomia The objectives are to evaluate the safety and identify either a maximum tolerated dose or a maximum feasible dose of a single dose of AAV2hAQP1 infused into one or both parotid glands:

To evaluate subject improvement of xerostomia symptoms, to evaluate the increase in parotid gland salivary output after treatment with AAV2hAQP1, to evaluate additional efficacy outcomes.

Conditions

Radiation-Induced Parotid Gland Hypofunction; Xerostomia Due to Radiotherapy; Head and Neck Cancer

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

1 x 10^11 vg/gland (single gland)

Group Type: EXPERIMENTAL

AAV2hAQP1: 1 x 10^11 vg/gland (single gland)

Intervention Type: DRUG

Intra-parotid administration of AAV2hAQP1 via Stensen's duct to a single parotid gland at a dose level of 1 x 10\^11 vg/gland

3 x 10^10 vg/gland (both glands)

Group Type: EXPERIMENTAL

AAV2hAQP1: 3 x 10^10 vg/gland (both glands)

Intervention Type: DRUG

Intra-parotid administration of AAV2hAQP1 via Stensen's duct to both parotid glands at a dose level of 3 x 10\^10 vg/gland

3 x 10^11 vg/gland (single gland)

Group Type: EXPERIMENTAL

AAV2hAQP1: 3 x 10^11 vg/gland (single gland)

Intervention Type: DRUG

Intra-parotid administration of AAV2hAQP1 of via Stensen's duct to a single parotid gland at a dose level of 3 x 10\^11 vg/gland

1 x 10^11 vg/gland (both glands)

Group Type: EXPERIMENTAL

AAV2hAQP1: 1 x 10^11 vg/gland (both glands)

Intervention Type: DRUG

intra-parotid administration of AAV2hAQP1 via Stensen's duct to both parotid glands at a dose level of 1 x 10\^11 vg/gland

1 x 10^12 vg/gland (single gland)

Group Type: EXPERIMENTAL

AAV2hAQP1: 1 x 10^12 vg/gland (single gland)

Intervention Type: DRUG

Intra-parotid administration of AAV2hAQP1 via Stensen's duct to a single parotid gland at a dose level of 1 x 10\^12 vg/gland

3 x 10^11 vg/gland (both glands)

Group Type: EXPERIMENTAL

AAV2hAQP1: 3 x 10^11 vg/gland (both glands)

Intervention Type: DRUG

Intra-parotid administration of AAV2hAQP1 via Stensen's duct to both parotid glands at a dose level of 3 x 10\^11 vg/gland

3 x 10^12 vg/gland (single gland)

Group Type: EXPERIMENTAL

AAV2hAQP1: 3 x 10^12 vg/gland (single gland)

Intervention Type: DRUG

Intra-parotid administration of AAV2hAQP1 via Stensen's duct to a single parotid gland at a dose level of 3 x 10\^12 vg/gland

1 x 10^12 vg/gland (both glands)

Group Type: EXPERIMENTAL

AAV2hAQP1: 1 x 10^12 vg/gland (both glands)

Intervention Type: DRUG

Intra-parotid administration of AAV2hAQP1 via Stensen's duct to both parotid glands at a dose level of 1 x 10\^12 vg/gland

Interventions

AAV2hAQP1: 1 x 10^11 vg/gland (single gland)

Intra-parotid administration of AAV2hAQP1 via Stensen's duct to a single parotid gland at a dose level of 1 x 10\^11 vg/gland

Intervention Type: DRUG

AAV2hAQP1: 3 x 10^10 vg/gland (both glands)

Intra-parotid administration of AAV2hAQP1 via Stensen's duct to both parotid glands at a dose level of 3 x 10\^10 vg/gland

Intervention Type: DRUG

AAV2hAQP1: 3 x 10^11 vg/gland (single gland)

Intra-parotid administration of AAV2hAQP1 of via Stensen's duct to a single parotid gland at a dose level of 3 x 10\^11 vg/gland

Intervention Type: DRUG

AAV2hAQP1: 1 x 10^11 vg/gland (both glands)

intra-parotid administration of AAV2hAQP1 via Stensen's duct to both parotid glands at a dose level of 1 x 10\^11 vg/gland

Intervention Type: DRUG

AAV2hAQP1: 1 x 10^12 vg/gland (single gland)

Intra-parotid administration of AAV2hAQP1 via Stensen's duct to a single parotid gland at a dose level of 1 x 10\^12 vg/gland

Intervention Type: DRUG

AAV2hAQP1: 3 x 10^11 vg/gland (both glands)

Intra-parotid administration of AAV2hAQP1 via Stensen's duct to both parotid glands at a dose level of 3 x 10\^11 vg/gland

Intervention Type: DRUG

AAV2hAQP1: 3 x 10^12 vg/gland (single gland)

Intra-parotid administration of AAV2hAQP1 via Stensen's duct to a single parotid gland at a dose level of 3 x 10\^12 vg/gland

Intervention Type: DRUG

AAV2hAQP1: 1 x 10^12 vg/gland (both glands)

Intra-parotid administration of AAV2hAQP1 via Stensen's duct to both parotid glands at a dose level of 1 x 10\^12 vg/gland

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Male or female subjects ≥18 years of age.

2. History of radiation therapy for head and neck cancer.

3. Abnormal parotid gland function as judged by both absence of unstimulated parotid salivary flow and a stimulated parotid salivary flow in the targeted parotid gland >0 and <0.3 mL/min/gland after 2% citrate stimulation.

4. No evidence of recurrence of the primary malignancy by an otolaryngology (ears, nose, and throat [ENT]) assessment. Additionally, all subjects must be disease-free of head and neck cancer for at least 5 years following the end of treatment at screening, with the exception of subjects with a history of HPV+ OPC (base of tongue, oropharynx, pharynx, soft palate, tonsil) who must be disease free for at least 2 years following the end of treatment. Disease status will be determined by negative clinical examinations and computed tomography (CT) scans of the neck and chest. If subjects have had a magnetic resonance imaging (MRI) of the neck or a positron emission tomography (PET) scan within 6 months of screening, then a CT scan is not required, except for HPV+ OPC subjects who must have scans at 2 years post treatment.

5. Female subjects of childbearing potential (i.e., ovulating, pre-menopausal, and not surgically sterile) and all male subjects must use a medically accepted contraceptive regimen during their participation in the study and until all samples collected at 2 consecutive visits following AAV2hAQP1 administration are negative. Acceptable methods of contraception for male subjects include the following:

• Condoms with spermicide. Acceptable methods of contraception for female subjects include the following:
• Intrauterine device for at least 12 weeks prior to Screening.
• Hormonal contraception (oral, implant, injection, ring, or patch) for at least 12 weeks prior to Screening.
• Diaphragm used in combination with spermicide.

Exclusion Criteria

1. Pregnant or lactating women or women planning to become pregnant.

2. Any experimental therapy within 3 months before Day 1.

3. Active infection that requires the use of intravenous antibiotics and does not resolve at least 1 week before Day 1.

4. Uncontrolled ischemic heart disease (i.e., unstable angina, evidence of active ischemic heart disease on electrocardiogram [ECG]).

5. History of systemic autoimmune diseases affecting the salivary glands.

6. Use of systemic immunosuppressive medications (i.e., corticosteroids).

o Note: Topical, inhaled, or intranasal corticosteroids are allowed.

7. Malignancy, other than head and neck cancer, within the past 3 years, with the exception of adequately treated basal cell or squamous cell carcinoma of the skin or in situ cervical carcinoma.

8. Active infections including, Epstein-Barr virus (EBV), cytomegalovirus (CMV), hepatitis B (HBV), hepatitis C (HCV), or human immunodeficiency virus (HIV) infection.

9. White blood cell count <3000/μL, absolute neutrophil count <1500/μL, hemoglobin <10.0 g/dL, platelet count <100,000/μL, or absolute lymphocyte count ≤500/μL.

10. Alanine aminotransferase and/or aspartate aminotransferase >1.5 × the upper limit of normal (ULN), alkaline phosphatase >1.5 × ULN, or total bilirubin >1.5 × ULN with any elevation of liver enzymes.

11. Estimated glomerular filtration rate <60 mL/min/1.73 m2 using the Modification of Diet in Renal Disease equation.

12. Active use of tobacco products as determined by self-reporting.

13. Allergy to iodine or shellfish, and thus unable to have sialographic evaluations.

14. Allergy or hypersensitivity to glycopyrrolate.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

MeiraGTx UK II Ltd

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Leland Stanford Junior University

Stanford, California, United States

University of Louisville

Louisville, Kentucky, United States

Brigham and Women's Hospital

Boston, Massachusetts, United States

Memorial Sloan Kettering Cancer Center

New York, New York, United States

Atrium Health

Charlotte, North Carolina, United States

Health Sciences North - Northeast Cancer Center

Greater Sudbury, Ontario, Canada

Countries

United States; Canada

Other Identifiers

MGT016

Identifier Type: -

Identifier Source: org_study_id